Merck & Co Inc Oncology Event at ASCO 2020 Transcript
Good afternoon. My name is Jerome, and I will be your conference operator today. At this time, I would like to welcome everyone to the Merck Oncology ASCO Event Conference Call. (Operator Instructions) Thank you. I would now like to turn the call over to Peter Dannenbaum, Vice President, Investor Relations. Please go ahead.
Thank you, Jerome, and good afternoon, everybody. Welcome to Merck's 2020 Virtual ASCO Investor Call. I'm joined by Dr. Roger Perlmutter, President of Merck Research Labs; Dr. Roy Baynes, Head of Global Clinical Development and Chief Medical Officer of Merck Research Labs; and Frank Clyburn, Chief Commercial Officer.
Before we begin, I would like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of Merck's management and are subject to significant
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |